Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C

被引:42
作者
Wu, J
Chen, S [1 ]
Gui-Qiang, W
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Infect Dis, Harbin 150086, Peoples R China
[2] PeiKing Univ, Hosp 1, Dept Infect Dis, PeiKing, Peoples R China
关键词
fatty liver; genotype; hepatitis C; insulin; sustained virologic response;
D O I
10.1111/j.1478-3231.2006.01219.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: Hepatic steatosis is a histological feature in patients with chronic hepatitis C (CHC) and adversely affects the virologic response rates to anti-hepatitis C virus (HCV) therapy. The aim of this study is to investigate whether the fatty liver and related factors have impact on the efficacy in CHC treated with peginterferon and ribavirin, and the associations between HCV genotyping and fatty liver. Methods: Ninety-eight patients received subcutaneously 180 mu g peginterferon alpha-2a once a week plus ribavirin. HCV genotypes and the levels of plasma insulin of patients were measured. Fatty liver was detected by B ultrasound. The body mass index (BMI), waist-to-hip ratio (WHR) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated. Results: Among 98 CHC patients, 38 (38.8%) were infected with genotype 1; 44 (44.9%) with genotype 2; 13 (13.3%) with genotype 3; 3 (3.0%) with indeterminate genotype. The prevalence of fatty liver was 10.5%, 11.4%, 38.5% in patients infected with HCV genotype 1, 2, 3, respectively, which suggested that the distribution of fatty liver in different HCV genotypes was imbalanced (chi(2)=6.758, P=0.034). In univariate analysis, the efficacy of combination therapy was significantly associated with BMI (P=0.011), WHR (P=0.024), the levels of plasma insulin (P=0.001), genotype (P=0.036), presence of fatty liver (P=0.028), treatment dosage and duration (P=0.012) and HOMA-IR (P=0.002). With binary logistic regression analysis, the plasma insulin levels and HOMA-IR showed independent predictors to the efficacy of antiviral therapy. Conclusion: The prevalence of fatty liver in HCV genotype 3 was markedly higher than that of other genotypes. The BMI, WHR, the levels of plasma insulin, genotype, presence of fatty liver, treatment dosage and duration and HOMA-IR were associated with the sustained virologic response. The level of plasma insulin and HOMA-IR were independent factors for predicting effect of antiviral therapy.
引用
收藏
页码:166 / 172
页数:7
相关论文
共 50 条
  • [31] Occult Hepatitis B Virus Infection in Patients With Chronic Hepatitis C Treated With Antiviral Therapy
    Caviglia, Gian Paolo
    Abate, Maria Lorena
    Manzini, Paola
    Danielle, Franca
    Ciancio, Alessia
    Rosso, Chiara
    Olivero, Antonella
    Pellicano, Rinaldo
    Touscoz, Giovanni Antonio
    Smedile, Antonina
    Rizzetto, Mario
    HEPATITIS MONTHLY, 2012, 12 (11) : e7292
  • [32] EFFICACY OF PEGINTERFERON ALPHA-2A AND RIBAVIRIN COMBINATION THERAPY IN TREATMENT-NAIVE ESTONIAN PATIENTS WITH CHRONIC HEPATITIS C
    Brjalin, Vadim
    Salupere, Riina
    Tallo, Tatjana
    Kuznetsova, Tatiana
    Priimaegi, Ljudmilla
    Tefanova, Valentina
    CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH, 2012, 20 (02) : 150 - 155
  • [33] Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis
    Soderholm, Jonas
    Millbourn, Charlotta
    Busch, Katharina
    Kovamees, Jan
    Schvarcz, Robert
    Lindahl, Karin
    Bruchfeld, Annette
    JOURNAL OF HEPATOLOGY, 2018, 68 (05) : 904 - 911
  • [34] Chronic Rejection Associated with Antiviral Therapy for Recurrent Hepatitis C after Living-Donor Liver Transplantation
    Ueda, Yoshihide
    Kaido, Toshimi
    Ito, Takashi
    Ogawa, Kohei
    Yoshizawa, Atsushi
    Fujimoto, Yasuhiro
    Mori, Akira
    Miyagawa-Hayashino, Aya
    Haga, Hironori
    Marusawa, Hiroyuki
    Chiba, Tsutomu
    Uemoto, Shinji
    TRANSPLANTATION, 2014, 97 (03) : 344 - 350
  • [35] Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis
    Childs, Kate
    Merritt, Elliot
    Considine, Aisling
    Sanchez-Fueyo, Alberto
    Agarwal, Kosh
    Martinez-Llordella, Marc
    Carey, Ivana
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (02):
  • [36] Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease
    Khoo, Tiffany
    Lam, Danielle
    Olynyk, John K.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (29) : 4831 - 4845
  • [37] Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6 A meta-analysis
    Luo, Aoran
    Xu, Pan
    Wang, Jin
    Li, Zuli
    Wang, Shunli
    Jiang, Xiaoyan
    Ren, Hong
    Luo, Qiang
    MEDICINE, 2019, 98 (20)
  • [38] Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
    Toshikuni, Nobuyuki
    GUT AND LIVER, 2017, 11 (03) : 335 - 348
  • [39] Detection of Frequency of Hepatitis C Patients with Fatty Liver and Impact of Interferon on Fatty Liver Improvement
    Siddique, Nasir
    Shakil, Muhammad
    Ullah, Muhammad Ikram
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2015, 9 (02): : 744 - 747
  • [40] Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists
    Hofmann, WP
    Bock, H
    Weber, C
    Tacke, W
    Pfaff, R
    Kihn, R
    Moog, G
    Kellner, HU
    Schöfer, M
    Frick, B
    Berg, P
    Rambow, A
    Friedrich-Rust, M
    Hermann, E
    Sarrazin, C
    Zeuzem, S
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2006, 44 (01): : 25 - 31